GyneBio Pharma

GyneBio Pharma is a French biotechnology company dedicated to the discovery and development of innovative, non-hormonal treatments for women's health conditions, with a primary focus on endometriosis. Founded in 2020, the company aims to provide effective therapeutic alternatives to existing hormonal treatments and surgical interventions, which often carry significant side effects or limited long-term efficacy. Their lead program, GBP-001, is a small molecule candidate designed to target the underlying biological mechanisms of endometriosis. GyneBio Pharma leverages the expertise of its founding team in immunology and drug development to address the high unmet medical needs of millions of women globally.